Prostate-specific membrane antigen-based imaging

Area of Science:

• Oncology
• Radiology
• Molecular Imaging

Background:

• Prostate cancer (CaP) is a common malignancy in North America.
• Conventional imaging lacks specificity for CaP, limiting patient management.
• Prostate-specific membrane antigen (PSMA) is overexpressed in CaP tissue.

Purpose of the Study:

• To explore novel imaging agents targeting PSMA for improved CaP detection.
• To evaluate the potential of antibodies and small molecules for PSMA-targeted imaging.

Main Methods:

• Review of existing PSMA-targeting agents, including antibodies (e.g., Hu mAb J591) and small molecules (e.g., MIP-1072, MIP-1095).
• Discussion of imaging characteristics, target binding, and potential for diagnostic applications using SPECT and PET.

Main Results:

• Humanized monoclonal antibodies (Hu mAb J591) show potential but have limitations in imaging speed.
• Small-molecule inhibitors (MIP-1072, MIP-1095) demonstrate high affinity for PSMA.
• (123)I-MIP-1072 and (123)I-MIP-1095 successfully imaged CaP xenografts, indicating suitability for human trials.

Conclusions:

• PSMA-targeted imaging agents, particularly small molecules, offer significant potential to enhance diagnostic sensitivity and specificity in prostate cancer.
• Further development of these agents could revolutionize CaP imaging and patient management.